Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management
- PMID: 33604098
- PMCID: PMC7863125
- DOI: 10.6004/jadpro.2020.11.4.5
Waldenström Macroglobulinemia: Clinical Presentation, Diagnosis, and Management
Abstract
Waldenström macroglobulinemia is a rare hematologic malignancy characterized by an IgM-associated lymphoplasmacytic lymphoma. Often, it is associated with an indolent disease course, and many patients are candidates for careful monitoring. As many patients present with advanced age and nonspecific constitutional symptoms, careful consideration should be given to treatment decisions, including when and how to treat for maximized clinical benefit with minimal toxicity. This article provides an evidence-based practical approach to appropriate monitoring of the asymptomatic patient and management of symptomatic patients who require treatment for this rare malignancy.
© 2020 Harborside™.
Conflict of interest statement
The authors have no conflicts of interest to disclose.
Similar articles
-
Waldenström macroglobulinemia: What a hematologist needs to know.Blood Rev. 2015 Sep;29(5):301-19. doi: 10.1016/j.blre.2015.03.001. Epub 2015 Mar 24. Blood Rev. 2015. PMID: 25882617 Review.
-
Waldenström macroglobulinemia treatment algorithm 2018.Blood Cancer J. 2018 May 1;8(4):40. doi: 10.1038/s41408-018-0076-5. Blood Cancer J. 2018. PMID: 29712895 Free PMC article. Review.
-
Waldenstrom Macroglobulinemia: Familial Predisposition and the Role of Genomics in Prognosis and Treatment Selection.Curr Treat Options Oncol. 2016 Mar;17(3):16. doi: 10.1007/s11864-016-0391-7. Curr Treat Options Oncol. 2016. PMID: 26942591 Review.
-
Lymphoplasmacytic lymphoma-Waldenström macroglobulinemia: an unusual presentation in ovaries, fallopian tubes and uterine cervix.Int J Clin Exp Med. 2013 May 22;6(5):346-50. Print 2013. Int J Clin Exp Med. 2013. PMID: 23724153 Free PMC article.
-
Emerging therapeutic options for Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.Expert Rev Anticancer Ther. 2015;15(10):1143-56. doi: 10.1586/14737140.2015.1071668. Epub 2015 Jul 21. Expert Rev Anticancer Ther. 2015. PMID: 26196236 Review.
Cited by
-
The performance and applied value of 18F-FDG PET/CT imaging in Waldenstrom macroglobulinemia.Am J Nucl Med Mol Imaging. 2023 Oct 20;13(5):217-224. eCollection 2023. Am J Nucl Med Mol Imaging. 2023. PMID: 38023819 Free PMC article.
-
Targeting BTK in B Cell Malignancies: From Mode of Action to Resistance Mechanisms.Int J Mol Sci. 2024 Mar 12;25(6):3234. doi: 10.3390/ijms25063234. Int J Mol Sci. 2024. PMID: 38542207 Free PMC article. Review.
-
Waldenstrom Macroglobulinemia: Clinical Presentation, Diagnosis, and Management in an Elderly Male.Cureus. 2023 Aug 25;15(8):e44127. doi: 10.7759/cureus.44127. eCollection 2023 Aug. Cureus. 2023. PMID: 37750145 Free PMC article.
-
Pathophysiology and Treatments of Complications of Waldenström's Macroglobulinemia.Clin Hematol Int. 2024 Oct 7;6(4):11-18. doi: 10.46989/001c.124268. eCollection 2024. Clin Hematol Int. 2024. PMID: 39417016 Free PMC article.
-
Nucleic Acid Biomarkers in Waldenström Macroglobulinemia and IgM-MGUS: Current Insights and Clinical Relevance.Diagnostics (Basel). 2022 Apr 12;12(4):969. doi: 10.3390/diagnostics12040969. Diagnostics (Basel). 2022. PMID: 35454017 Free PMC article. Review.
References
-
- Castillo, J. J., Olszewski, A. J., Kanan, S., Meid, K., Hunter, Z. R., & Treon, S. P. (2015). Overall survival and competing risks of death in patients with Waldenstrom macroglobulinaemia: An analysis of the Surveillance, Epidemiology and End Results database. British Journal of Haematology, 169(1), 81–89. 10.1111/bjh.13264 - DOI - PubMed
-
- Dhodapkar, M. V., Hoering, A., Gertz, M. A., Rivkin, S., Szymonifka, J., Crowley, J., & Barlogie, B. (2009). Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood, 113(4), 793–796. 10.1182/blood-2008-07-172080 - DOI - PMC - PubMed
LinkOut - more resources
Full Text Sources
Research Materials